Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM09YTN)

• Drug Name: Abelacimab Drug Info
• Synonyms: MAA868

Indication

Disease Entry	ICD 11	Status	REF
Atrial fibrillation	BC81.3	Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DM09YTN

Molecule-Related Drug Atlas

Drug(s) Targeting Coagulation factor XI (F11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
A186	DMHJ0EB	Clotting disorder	3B4Z	IND submitted	[3]
Asundexian	DMLZMU2	Ischemic stroke	8B11.5Z	Phase 3	[4]
MK-2060	DM79A32	Thrombosis	DB61-GB90	Phase 2	[5]
EP-7041	DMV0MHI	Thrombosis	DB61-GB90	Phase 1	[6]
AB023	DMBG9HI	End-stage renal disease	GB61.5	Phase 1	[7]
A336	DMVQG8G	Clotting disorder	3B4Z	Phase 1	[3]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Coagulation factor XI (F11)	TTJCPUT	FA11_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT04755283) A Multicenter, RandomiZed, Active-ControLled Study to Evaluate the Safety and Tolerability of Two Blinded Doses of Abelacimab (MAA868) Compared With Open-Label Rivaroxaban in Patients With Atrial Fibrillation (AZALEA). U.S.National Institutes of Health.
• [2] Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa. J Thromb Haemost. 2022 Feb;20(2):307-315.
• [3] Clinical pipeline report, company report or official report of Klus Pharma
• [4] Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa. J Thromb Haemost. 2022 Jun;20(6):1400-1411.
• [5] Clinical pipeline report, company report or official report of MSD
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial. Arterioscler Thromb Vasc Biol. 2019 Apr;39(4):799-809.